Improvement of Subjective Well-Being by Ranolazine Among Unrevascularized Chronic Stable Coronary Artery Disease Patients

Trial Profile

Improvement of Subjective Well-Being by Ranolazine Among Unrevascularized Chronic Stable Coronary Artery Disease Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Ranolazine (Primary)
  • Indications Angina pectoris; Coronary artery disease; Myocardial ischaemia
  • Focus Therapeutic Use
  • Acronyms IMWELL
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 01 Jun 2017 Results published in the Cardiology and Therapy
    • 20 Sep 2016 Status changed from recruiting to completed.
    • 27 Oct 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top